4:56 PM
 | 
Jul 26, 2018
 |  BC Extra  |  Company News

Reese succeeding Harper as Amgen EVP of R&D

Amgen Inc. (NASDAQ:AMGN) said EVP of R&D Sean Harper will retire and be succeeded by SVP of Translational Sciences and Oncology David Reese. The company also reported 2Q18 earnings on Thursday after market hours that outperformed analysts' expectations.

Harper joined Amgen in 2002 as VP of development after serving as senior director of clinical genomics at the Merck Research Laboratories of Merck & Co. Inc. (NYSE:MRK). He has been EVP of R&D at Amgen since 2012.

The company also said EVP of Global Commercial Operations Anthony Hooper will...

Read the full 417 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >